

A13  
which is concentrated in order to carry out sequentially an optional treatment at an acid pH and at least one of the following steps of viral inactivation, consisting of pasteurisation and a treatment with solvent/detergent, the product afterwards being precipitated and washed with PEG in order to eliminate any chemical viral inactivation reagents and then, by solubilisation and change of pH, the protein contaminants, and finally purified by ultrafiltration to reduce the volume and the PEG content, then carrying out an optional virus filtration and subsequent concentration.

---

### REMARKS


Tables 1, 3, 6-7, 9-11 and 13 have been reformatted to so as to be more legible and facilitate examination of this application. Claims 20, 24 and 42 have been amended to correct obvious typographical errors. Claims 44-45 have been amended to further specify that preparations are pH adjusted either to 4.0 - 4.8 (as specified at line 18 on page 21 of the application as filed) or to 4.4-5.0 (as specified at line 29 on page 21 of the application as filed). Claim 46 has been amended to specify that the solution is heated at " $25 \pm 5$  °C", as described on page 21, line 30 of the application as filed. Finally the Abstract of the Disclosure has also been amended to delete the specification of particular protein concentrations, which are not necessary to summarize this invention.

No new matter has been introduced by these amendments. It is believed, moreover, that these amendments are being submitted before the mailing date of a first

Office Action on the merits and that, moreover, this submission does not unduly interfere with the preparation of any such Office Action. Entry and consideration of these amendments are therefore respectfully requested.

Respectfully submitted,

Dated: May 1, 2003

  
\_\_\_\_\_  
Samuel S. Woodley, Ph.D.  
(Reg. No. 43,287)  
Attorney/Agent for Applicants

**DARBY & DARBY, P.C.**  
805 Third Avenue  
New York, N.Y. 10022  
Phone (212) 527-7700